New hope for uncontrolled muscle movements: valbenazine trial targets stubborn TD symptoms

NCT ID NCT07105111

Recruiting now Disease control Sponsor: Neurocrine Biosciences Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 25 times

Summary

This study tests whether valbenazine can reduce involuntary muscle movements (tardive dyskinesia) in adults who still have symptoms while taking or after stopping another similar drug. About 50 people with schizophrenia, bipolar disorder, or major depression will take valbenazine capsules for 24 weeks. Doctors and patients will report changes in movement severity and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Neurocrine Clinical Site
RECRUITING

Bryant, Arkansas, 72022, United States
Neurocrine Clinical Site
RECRUITING

Chino, California, 91710, United States
Neurocrine Clinical Site
RECRUITING

Fountain Valley, California, 92708, United States
Neurocrine Clinical Site
RECRUITING

Fresno, California, 93701, United States
Neurocrine Clinical Site
RECRUITING

Long Beach, California, 90807, United States
Neurocrine Clinical Site
RECRUITING

Orange, California, 92866, United States
Neurocrine Clinical Site
RECRUITING

Redlands, California, 92373, United States
Neurocrine Clinical Site
RECRUITING

San Diego, California, 92123, United States
Neurocrine Clinical Site
RECRUITING

Bonita Springs, Florida, 34134, United States
Neurocrine Clinical Site
RECRUITING

Hialeah, Florida, 33012, United States
Neurocrine Clinical Site
RECRUITING

Miami, Florida, 33144, United States
Neurocrine Clinical Site
RECRUITING

Miami, Florida, 33176, United States
Neurocrine Clinical Site
RECRUITING

Orange City, Florida, 32763, United States
Neurocrine Clinical Site
RECRUITING

Port Charlotte, Florida, 33980, United States
Neurocrine Clinical Site
RECRUITING

Tampa, Florida, 33629, United States
Neurocrine Clinical Site
RECRUITING

Augusta, Georgia, 30912, United States
Neurocrine Clinical Site
RECRUITING

Marietta, Georgia, 30060, United States
Neurocrine Clinical Site
RECRUITING

Naperville, Illinois, 60563, United States
Neurocrine Clinical Site
RECRUITING

Omaha, Nebraska, 68124, United States
Neurocrine Clinical Site
RECRUITING

Independence, Ohio, 44131, United States
Neurocrine Clinical Site
RECRUITING

Austin, Texas, 78754, United States
Neurocrine Clinical Site
RECRUITING

Richmond, Virginia, 23226, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

valbenazine

What this could lead to

If successful, this could offer a new treatment option for people with tardive dyskinesia whose symptoms persist despite current medications.

What could go wrong

This is a small, open-label study (no placebo group), so results may be less reliable. It also focuses on people who already tried another drug, so benefits may not apply to everyone.

Conditions

The condition(s) this trial relates to.

bipolar disorder major depressive disorder Psychotic Disorders Schizophrenia tardive dyskinesia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIPOLAR DISORDER MAJOR DEPRESSIVE DISORDER SCHIZOAFFECTIVE DISORDER SCHIZOAFFECTIVE DISORDER SCHIZOPHRENIA TARDIVE DYSKINESIA